Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27195866 | 0.79 | NOTUM (0.46) | QDPR | |
| SCHEMBL16904548 | 0.78 | SLC6A4 (0.58) | ARSLC6A4 | |
| SCHEMBL24309448 | 0.75 | QDPR (0.59) | QDPRSLC6A4 | |
| SCHEMBL10104530 | 0.74 | SLC6A4 (0.43) | QDPRSLC6A4 | |
| SCHEMBL31395110 | 0.74 | PDE3B (0.44) | AR | |
| SCHEMBL3766233 | 0.73 | DRD2 (0.44) | QDPRSLC6A4 | |
| SCHEMBL8382616 | 0.72 | QDPR (1.00) | QDPR | |
| SCHEMBL25382855 | 0.71 | PIK3CA (0.40) | AR | |
| SCHEMBL22288937 | 0.71 | PDE3B (0.38) | QDPRSLC6A4 | |
| SCHEMBL7816392 | 0.71 | QDPR (0.54) | QDPRSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | QDPR 1331/4885AR 4542/4885SLC6A4 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.